Eric K Rowinsky

Summary

Affiliation: Cancer Therapy and Research Center
Country: USA

Publications

  1. ncbi request reprint The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
    Eric K Rowinsky
    Institute for Drug Development of the Cancer Therapy and Research Foundation, San Antonio, Texas, USA
    Annu Rev Med 55:433-57. 2004
  2. ncbi request reprint Targeting the molecular target of rapamycin (mTOR)
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, 4th Floor Zeller Building, San Antonio, TX 78229, USA
    Curr Opin Oncol 16:564-75. 2004
  3. ncbi request reprint Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 10:4220s-4226s. 2004
  4. ncbi request reprint Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Rd, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
    J Clin Oncol 22:3003-15. 2004
  5. doi request reprint Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors
    Quincy Chu
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 16:2656-65. 2010
  6. doi request reprint Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    Chia Chi Lin
    The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 65:167-75. 2009
  7. doi request reprint Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 15:723-30. 2009
  8. ncbi request reprint Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 12:7406-13. 2006
  9. doi request reprint Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies
    Bahram Forouzesh
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Clin Cancer Res 15:3591-9. 2009
  10. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
    Chris H Takimoto
    Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:2675-83. 2007

Detail Information

Publications85

  1. ncbi request reprint The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
    Eric K Rowinsky
    Institute for Drug Development of the Cancer Therapy and Research Foundation, San Antonio, Texas, USA
    Annu Rev Med 55:433-57. 2004
    ..Early clinical studies suggest that both approaches are well tolerated and can induce clinical activity in many common malignancies...
  2. ncbi request reprint Targeting the molecular target of rapamycin (mTOR)
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, 4th Floor Zeller Building, San Antonio, TX 78229, USA
    Curr Opin Oncol 16:564-75. 2004
    ..The molecular target of rapamycin, which is a member of the phosphoinositide 3-kinase related kinase family and a central modulator of cell growth, is a unique and prime strategic target for anticancer therapeutic development...
  3. ncbi request reprint Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 10:4220s-4226s. 2004
    ..To validate the concept of RDTB therapeutics and to realize their full potential, radically different development, evaluation, and regulatory paradigms must be adopted...
  4. ncbi request reprint Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Rd, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
    J Clin Oncol 22:3003-15. 2004
    ....
  5. doi request reprint Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors
    Quincy Chu
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 16:2656-65. 2010
    ..The study also sought to determine the maximum tolerated dose (MTD) level on this schedule, as well as to recommend doses for disease-directed studies...
  6. doi request reprint Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    Chia Chi Lin
    The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 65:167-75. 2009
    ....
  7. doi request reprint Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 15:723-30. 2009
    ..v. infusion every 3 weeks. The study also sought to determine the maximum tolerated dose and the recommended dose, to describe the pharmacokinetic (PK) behavior of the compound, and to seek preliminary evidence of anticancer activity...
  8. ncbi request reprint Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 12:7406-13. 2006
    ....
  9. doi request reprint Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies
    Bahram Forouzesh
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Clin Cancer Res 15:3591-9. 2009
    ..The study also sought to determine the maximum tolerated dose (MTD) levels of trabectedin on these schedules, as well as to recommend doses for disease-directed studies...
  10. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
    Chris H Takimoto
    Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:2675-83. 2007
    ..Pemetrexed plasma pharmacokinetics were evaluated for cycle 1...
  11. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired renal function...
  12. ncbi request reprint A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 59:165-74. 2007
    ....
  13. ncbi request reprint A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 13:532-9. 2007
    ..The study also sought to detect major pharmacokinetic drug-drug interactions between these agents and preliminary evidence of antitumor activity in patients with advanced solid malignancies...
  14. doi request reprint Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
    Monica M Mita
    Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center, San Antonio, TX, USA
    J Clin Oncol 26:361-7. 2008
    ....
  15. ncbi request reprint Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies
    Quincy Siu Chung Chu
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:4913-21. 2004
    ....
  16. doi request reprint Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies
    Monica Mita
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, Texas, USA
    Clin Cancer Res 17:193-200. 2011
    ..The starting dose of E7820 was 10 mg/d, which was increased to 20, 40, 70, 100, and 200 mg/d in cohorts of new patients...
  17. ncbi request reprint A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties
    Samira Syed
    Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:6512-21. 2004
    ..The study also sought to characterize the pharmacokinetic behavior of Col-3 and seek evidence of anticancer activity...
  18. doi request reprint A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer
    Quincy S C Chu
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 14:4484-90. 2008
    ....
  19. doi request reprint Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Monica Mita
    Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 64:287-95. 2009
    ..This study was designed to determine the MTD and pharmacology of PPX administered weekly to patients with solid malignancies...
  20. ncbi request reprint Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma
    Johann S de Bono
    Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Semin Oncol 30:79-92. 2003
    ..Randomized clinical studies investigating the clinical benefits of farnesyltransferase inhibition, with or without a taxane and trastuzumab, in patients with treatment-naive HER2-positive metastatic breast carcinoma are now warranted...
  21. ncbi request reprint Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio 78229, USA
    Clin Cancer Res 12:5207-15. 2006
    ..v. infusion weekly for 3 weeks every 4 weeks...
  22. ncbi request reprint A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
    Garry H Schwartz
    Brooke Army Medical Center, San Antonio, TX, USA
    Invest New Drugs 22:437-48. 2004
    ....
  23. ncbi request reprint A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies
    Lillian L Siu
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 8:2157-66. 2002
    ..v. infusion daily for 5 days every 3 weeks in patients with advanced cancer...
  24. ncbi request reprint A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:4761-71. 2003
    ..The study also sought to identify drug-drug pharmacokinetic interactions, evaluate effects on protein farnesylation, and seek preliminary evidence for clinical activity...
  25. doi request reprint Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies
    Lisa A Hammond-Thelin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Invest New Drugs 30:316-26. 2012
    ..This study was performed to principally evaluate the feasibility of administering TAS-106 as a bolus intravenous (IV) infusion every 3 weeks...
  26. ncbi request reprint Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 21:211-22. 2003
    ..v.) once every 3 weeks and to seek evidence of antitumor activity...
  27. ncbi request reprint A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:5048-57. 2004
    ....
  28. ncbi request reprint A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
    Mitchell A Garrison
    Brooke Army Medical Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2527-37. 2003
    ..The MTD was defined for both minimally pretreated (MP) and heavily pretreated (HP) patients as the highest dose level at which the incidence of dose-limiting toxicity does not exceed 20%...
  29. ncbi request reprint A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor
    Desiree Hao
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2465-71. 2003
    ..The purpose of this study was to assess the feasibility and characterize the pharmacokinetics of squalamine administered as a continuous i.v. infusion daily for 5 days every 3 weeks...
  30. ncbi request reprint ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 10:7555-65. 2004
    ....
  31. ncbi request reprint Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 21:175s-186s. 2003
    ....
  32. ncbi request reprint A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies
    Bahram Forouzesh
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:5540-9. 2003
    ..The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  33. doi request reprint A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 69:825-34. 2012
    ..The primary objective of this study was to determine whether repeated doses of bexarotene capsules affect pharmacokinetic parameters of paclitaxel or carboplatin in patients with advanced non-small cell lung cancer...
  34. ncbi request reprint Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 14:7947-55. 2008
    ..To evaluate the safety and describe the pharmacokinetic profile of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, in combination with cisplatin (CDDP) in adults with advanced solid tumors...
  35. ncbi request reprint A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, Texas 78229, USA
    Clin Cancer Res 8:2142-8. 2002
    ..Additional disease-directed clinical evaluations of AN-9 are necessary to establish the breadth of its antitumor activity and to assess its role as an effective differentiating agent...
  36. ncbi request reprint Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, and Department of Pharmacology, University of Texas Health Science Center at San Antonio 78229, USA
    Clin Cancer Res 11:8728-36. 2005
    ..Major toxicologic and pharmacologic differences between the two sequences of drug administration were also assessed...
  37. ncbi request reprint Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies
    Quincy S C Chu
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    J Clin Oncol 25:3753-8. 2007
    ..This phase I trial (EGF10005) assessed the safety, optimally tolerated regimen (OTR), and pharmacokinetics of lapatinib and capecitabine in combination in patients with advanced solid malignancies...
  38. ncbi request reprint Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs
    Emiliano Calvo
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, TX 78229, USA
    Clin Lung Cancer 6:S35-42. 2004
    ..The result should be more efficient and scientifically founded clinical development strategies for rationally designed target-based therapeutic agents...
  39. ncbi request reprint Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
    Emiliano Calvo
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 10:7112-20. 2004
    ....
  40. ncbi request reprint Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients
    Shazli N Malik
    The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 9:2478-86. 2003
    ..This study evaluated the pharmacodynamic effects of OSI-774 in normal skin tissues collected from patients treated with the agent in a Phase I study...
  41. ncbi request reprint Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 24:2052-8. 2006
    ....
  42. ncbi request reprint A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
    Manuel Hidalgo
    Institute for Drug Development, Cancer Therapy and Research Center, Brook Army Medical Center, San Antonio, TX, USA
    Clin Cancer Res 12:5755-63. 2006
    ..v. once daily for 5 days every 2 weeks to determine the maximum tolerated dose, toxicity profile, pharmacokinetics, and preliminary antitumor efficacy...
  43. ncbi request reprint Raf: a strategic target for therapeutic development against cancer
    Muralidhar Beeram
    University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    J Clin Oncol 23:6771-90. 2005
    ....
  44. ncbi request reprint Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA
    Clin Cancer Res 13:3293-301. 2007
    ..v. infusion without premedication every 3 weeks, determine the maximum tolerated dose and the phase II recommended dose of AI-850, study the pharmacokinetics of paclitaxel in this new formulation, and seek evidence of anticancer activity...
  45. ncbi request reprint Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor
    Emiliano Calvo
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
    Curr Oncol Rep 7:123-8. 2005
    ..This review highlights the results of current approaches for improvement of the therapeutic indices of these agents...
  46. pmc The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Breast Cancer Res 5:154-9. 2003
    ..It is hoped that these studies will support the identification of the molecules driving a tumor's growth, and the selection of the appropriate combination of targeted agents in the near future...
  47. ncbi request reprint A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, TX, USA
    J Clin Oncol 21:148-57. 2003
    ..The study also sought to determine the maximum-tolerated dose (MTD) of PEG-CPT, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  48. ncbi request reprint Therapeutics targeting signal transduction for patients with colorectal carcinoma
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, 4th Floor Zeller Building, San Antonio, TX 78229, USA
    Br Med Bull 64:227-54. 2002
    ..Potential advantages and disadvantages of these different therapeutic modalities are discussed and future challenges for the evaluation of these targeted agents in the clinic is presented...
  49. ncbi request reprint A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms
    Lisa A Hammond
    Cancer Therapy and Research Center, University of San Antonio Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 10:1645-56. 2004
    ....
  50. ncbi request reprint Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 4th Floor Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Clin Colorectal Cancer 4:107-23. 2004
    ..It will also emphasize the complexity of these systems and the need to incorporate novel clinical development paradigms based on a thorough scientific understanding of these targets...
  51. doi request reprint A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Invest New Drugs 30:1597-606. 2012
    ..To our knowledge, this is one of the first trials to evaluate a completely noncytotoxic regimen in the first-line treatment of advanced pancreatic cancer. (ClinicalTrials.gov number, NCT00326911)...
  52. ncbi request reprint Mammalian target of rapamycin: a new molecular target for breast cancer
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Clin Breast Cancer 4:126-37. 2003
    ..The preliminary results of early clinical evaluations with rapamycin analogues and the unique developmental challenges that lie ahead will also be discussed...
  53. ncbi request reprint Signal events: Cell signal transduction and its inhibition in cancer
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Oncologist 8:5-17. 2003
    ..However, responsiveness to these novel therapies is dependent on a multitude of factors that ultimately determine the robustness and quality of the downstream response...
  54. ncbi request reprint Clinical experience with monoclonal antibodies to epidermal growth factor receptor
    Emiliano Calvo
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
    Curr Oncol Rep 7:96-103. 2005
    ..Other mAbs against EGFR, particularly panitumumab (ABX-EGF), h-R3, and EMD72000, are in advanced stages of clinical development...
  55. ncbi request reprint A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies
    Miguel A Villalona-Calero
    Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 78229, USA
    Clin Cancer Res 8:75-85. 2002
    ..v. infusion for 5 days every 3 weeks; (b) recommend a dose for Phase II studies; (c) characterize its pharmacokinetic behavior; and (d) seek preliminary evidence of anticancer activity...
  56. ncbi request reprint Crossing the cancer cell membrane to improve clinical outcomes
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Oncologist 8:1-4. 2003
  57. ncbi request reprint Acute retinal toxicity from the novel anti-tumor agent, Irofulven
    Robert F Melendez
    Department of Ophthalmology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Doc Ophthalmol 108:249-51. 2004
  58. ncbi request reprint A widening prospect: Imatinib and novel applications of targeted therapy
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Semin Oncol 31:1-3. 2004
  59. ncbi request reprint Erosion of the principal investigator role in a climate of industry dominance
    Eric K Rowinsky
    University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Eur J Cancer 41:2206-9. 2005
    ..This commentary discusses the impact of the pharmaceutical and biotechnology industries on the academic investigator, new challenges, and potential threats to optimal therapeutic development...
  60. ncbi request reprint The ErbB receptor family: a therapeutic target for cancer
    Johann S de Bono
    Institute for Drug Development of the Cancer Therapy and Research Foundation and Division of Medical Oncology, The University of Texas Health Science Center at San Antonio, 7979 Wurzbach, San Antonio, TX 78229, USA
    Trends Mol Med 8:S19-26. 2002
    ..Potential advantages and disadvantages of these different therapeutic modalities, as well as future challenges of evaluating ErbB-targeted agents in the clinic, are presented...
  61. ncbi request reprint Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?
    Eric K Rowinsky
    Institute for Drug Development, The Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, Texas, USA
    Oncologist 7:324-30. 2002
    ..These preliminary data suggest that weekly topotecan is active; further evaluations are planned to confirm the activity and therapeutic index and to determine optimal dosing of a weekly schedule...
  62. ncbi request reprint Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 8122 Datapoint Drive, Suite 700, San Antonio, TX 78229, USA
    J Clin Oncol 20:96-109. 2002
    ..To assess the feasibility of administering troxacitabine, a unique L-nucleoside that is not a substrate for deoxycytidine deaminase-mediated catabolism, as a 30-minute intravenous (IV) infusion daily for 5 days...
  63. ncbi request reprint Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors
    Desiree Hao
    Institute for Drug Development, Cancer Therapy and Research Center, 8122 Datapoint Drive, Suite 700, San Antonio, TX 78229 3264, USA
    Cancer Invest 20:387-404. 2002
    ..cytotoxic manner. This review will discuss the rationale and application of inhibiting signal transduction using inhibitors of RTK and Ras as prototypes of this class of agents...
  64. ncbi request reprint The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
    Anthony W Tolcher
    J Clin Oncol 20:4276-8. 2002
  65. ncbi request reprint ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial
    Malcolm Ranson
    Christie Hospital and Royal Eye Hospital, Manchester, United Kingdom
    J Clin Oncol 20:2240-50. 2002
    ..To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors...
  66. ncbi request reprint Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
    Alex Sparreboom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:4707-13. 2007
    ..Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese...
  67. ncbi request reprint Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes"
    Eric K Rowinsky
    Clin Cancer Res 8:2759-63. 2002
  68. ncbi request reprint Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
    Diane R Mould
    Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
    Clin Pharmacol Ther 71:334-48. 2002
    ..Our objective was to describe the pharmacokinetics and pharmacodynamics of topotecan in patients...
  69. ncbi request reprint Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I
    Robert B Lobell
    Department of Cancer Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Mol Cancer Ther 1:747-58. 2002
    ..These results confirm the pharmacologic profile of L-778,123 in humans as a dual inhibitor of FPTase and GGPTase-I, but indicate that the intended target of the drug, Ki-Ras, was not inhibited...
  70. ncbi request reprint A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer
    E Claire Dees
    Division of Hematology and Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Invest New Drugs 21:75-84. 2003
    ..Pharmacokinetic analysis showed that sequence does not impact on the pharmacokinetics of PZA when given in combination with cisplatin...
  71. ncbi request reprint Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    Kenneth A Foon
    Abgenix, Inc, Fremont, CA, USA
    Int J Radiat Oncol Biol Phys 58:984-90. 2004
    ..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy...
  72. ncbi request reprint Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas
    James A Posey
    University of Alabama at Birmingham Comprehensive Cancer Center, 35294, USA
    Clin Cancer Res 11:7866-71. 2005
    ..To determine the maximal tolerated dose and dose-limiting toxicities (DLT) of pegamotecan (polyethylene glycol-camptothecin) in patients with advanced malignancies when administered in cycles of once weekly for 3 of 4 weeks...
  73. ncbi request reprint Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents
    Eric K Rowinsky
    ImClone Systems, Branchburg, NJ 08876, USA
    J Clin Oncol 23:9394-407. 2005
    ..The preclinical activity, the status of ongoing evaluations, and the potential clinical impact of these novel agents are reviewed...
  74. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  75. ncbi request reprint Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer
    Christopher J Sweeney
    Indiana University Cancer Center, Indianapolis, IN, USA
    Clin Cancer Res 12:536-42. 2006
    ....
  76. ncbi request reprint Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  77. ncbi request reprint Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue
    Carlton K K Lee
    Department of Oncology, Johns Hopkins University and Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    Clin Cancer Res 12:2158-65. 2006
    ....
  78. ncbi request reprint The molecular target of rapamycin (mTOR) as a therapeutic target against cancer
    Monica M Mita
    Institute for Drug Development Cancer Therapy and Research Center San Antonio, Texas 78229, USA
    Cancer Biol Ther 2:S169-77. 2003
    ..The preliminary results of early clinical evaluations with RAP analogs and the unique developmental challenges that lie ahead will also be discussed...
  79. ncbi request reprint Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors
    Charles Erlichman
    Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA
    J Clin Oncol 24:2252-60. 2006
    ....
  80. ncbi request reprint Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)
    George W Sledge
    Cancer Pavillion, Indiana University Medical Center, 535 Barnhill Drive, Room RT473, Indianapolis, IN 46202 5112, USA
    J Clin Oncol 21:588-92. 2003
    ..Patients receiving single-agent doxorubicin or paclitaxel were crossed over to the other agent at time of progression...
  81. ncbi request reprint Novel agents that target tublin and related elements
    Eric K Rowinsky
    ImClone Systems Inc, Branchburg, NJ 08876, USA
    Semin Oncol 33:421-35. 2006
    ..Besides taxanes with novel delivery systems and unique physicochemical characteristics, the epothilones and other natural products, as well as developmental therapeutics against new mitotic targets, will be reviewed...
  82. ncbi request reprint Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
    Sharyn D Baker
    Division of Experimental Therapeutics, The Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21237, USA
    J Natl Cancer Inst 94:1883-8. 2002
    ..We conclude that body surface area should not be used to determine starting doses of investigational agents in future phase I studies...
  83. ncbi request reprint Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Heinz Josef Lenz
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 24:4914-21. 2006
    ..It also evaluated the safety, pharmacokinetics, immunokinetics, and biologic determinants of activity...
  84. ncbi request reprint Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
    Tomislav Dragovich
    Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
    Cancer Chemother Pharmacol 60:295-303. 2007
    ..The purpose of this phase IB trial was to evaluate the tolerability, pharmacokinetics and preliminary evidence of antitumor activity of erlotinib plus gemcitabine in patients with pancreatic cancer and other solid tumors...
  85. ncbi request reprint Novel anticancer agents in clinical development
    Alex A Adjei
    Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
    Cancer Biol Ther 2:S5-15. 2003
    ..This review will highlight promising rationally designed, target-based agents in clinical development, as well as the unique challenges involved in their successful development...